Early detection is critical in providing curative therapies for the vast majority of solid malignancies. Recent data from our own group and others suggest that circulating tumor cells (CTCs) may be shed in significant numbers into the blood stream of patients with invasive but localized cancers. Dissemination of abnormal cells has even been reported in patients with preneoplastic breast lesions (DCIS). Together, these observations suggest that, rather than being rare and late events in the evolution of cancer, the presence of CTCs may be an early herald of tumor vascular invasion, preceding a considerable period of time for the eventual establishment of viable distant metastases. This concept provides a radical departure from current approaches to early cancer detection, which are based on either radiographic screening or the development of reliable serum proteomic approaches. Testing for the presence of bona fide CTCs in the circulation would constitute a very powerful tool for early detection of cancer, but also requires the development of highly sensitive and reliable technology. The current approaches to microfluidic CTC detection that we have developed have sufficient capability to detect the presence of CTCs in some patients with early cancers, but they need to be greatly enhanced in both sensitivity and throughput to become valid for eventual application to population screening. Here, we propose technological innovations to allow such sensitive and robust CTC detection strategies, making use of enhanced microfluidic isolation and capture (Aim 1), as well as molecular tools for quantitation of minimal CTC numbers (Aim 2). Human studies will be given priority and will provide a rigorous test of our technological innovations and biological discoveries. This is a philosophical decision in that the project investigators strongly believe that to achieve the Quantum Project vision of """"""""solving or profoundly improving a specific health condition using technology-driven approaches"""""""" in a time period of 5 years, the project must have a sharp focus on """"""""real"""""""" systems at the onset of the program We propose a graded clinical application of these developing technologies, first in patients with known localized lung or breast cancer, and then in patients with newly diagnosed suspicious radiographic lesions that have been selected for biopsy (Aim 3). If successful, the combined bioengineering and molecular approaches proposed here would lead to indications for large scale screening studies in patients with environmental or genetic susceptibility to lung or breast cancers. Together, we have established a multidisciplinary team of researchers focused on extending CTC detection technologies to the challenge of early detection of invasive but localized cancers, with the potential for revolutionary approaches to cancer prevention.

Public Health Relevance

The next major hurdle in the management and treatment of cancer patients is early detection. The proposed point-of-care microchip to non-invasively isolate circulating tumor cells from the peripheral blood of cancer patients and ultimately general population for early detection has the potential to revolutionize the management of cancer patients with concomitant increase in survival rates.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01EB012493-01
Application #
8018225
Study Section
Special Emphasis Panel (ZEB1-OSR-E (A1))
Program Officer
Korte, Brenda
Project Start
2010-09-30
Project End
2015-08-31
Budget Start
2010-09-30
Budget End
2011-08-31
Support Year
1
Fiscal Year
2010
Total Cost
$2,498,556
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Sandlin, Rebecca D; Wong, Keith H K; Tessier, Shannon N et al. (2018) Ultra-fast vitrification of patient-derived circulating tumor cell lines. PLoS One 13:e0192734
Kwan, Tanya T; Bardia, Aditya; Spring, Laura M et al. (2018) A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. Cancer Discov 8:1286-1299
Hong, Xin; Sullivan, Ryan J; Kalinich, Mark et al. (2018) Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc Natl Acad Sci U S A 115:2467-2472
Bhan, Irun; Mosesso, Kelly; Goyal, Lipika et al. (2018) Detection and Analysis of Circulating Epithelial Cells in Liquid Biopsies From Patients With Liver Disease. Gastroenterology 155:2016-2018.e11
Aceto, Nicola; Bardia, Aditya; Wittner, Ben S et al. (2018) AR Expression in Breast Cancer CTCs Associates with Bone Metastases. Mol Cancer Res 16:720-727
Wong, Keith H K; Edd, Jon F; Tessier, Shannon N et al. (2018) Anti-thrombotic strategies for microfluidic blood processing. Lab Chip 18:2146-2155
Franses, Joseph W; Basar, Omer; Kadayifci, Abdurrahman et al. (2018) Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms. Oncologist 23:121-127
Wong, Keith H K; Tessier, Shannon N; Miyamoto, David T et al. (2017) Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells. Nat Commun 8:1733
Fachin, Fabio; Spuhler, Philipp; Martel-Foley, Joseph M et al. (2017) Monolithic Chip for High-throughput Blood Cell Depletion to Sort Rare Circulating Tumor Cells. Sci Rep 7:10936
Zheng, Yu; Miyamoto, David T; Wittner, Ben S et al. (2017) Expression of ?-globin by cancer cells promotes cell survival during blood-borne dissemination. Nat Commun 8:14344

Showing the most recent 10 out of 40 publications